A soluble immune complex was used as a drug carrier targeted to Fc-receptor-positive cells. Two receptor-positive tumor cell lines, WEHI-3 and M5076, were exposed to methotrexate-human serum albumin conjugate (MTX-HSA) in the presence and absence of anti-HSA antiserum. Both cell types were killed by 30 nM MTX when the drug conjugate was given in the presence of antiserum but were totally unaffected in the absence of antiserum. Drug-free HSA given with antiserum had no effect. Both cell lines responded similarly despite their marked difference in phagocytotic activity. One of the two lines, M5076, is defective in MTX transport and hence resistant to free MTX. Since this line would not be affected by MTX released extracellularly from MTX-HSA, its susceptibility implies that MTX is released inside cells, after endocytosis of the complex, and that endocytosis circumvents the transport defect. Two cell lines lacking Fc receptors (CHO and L929) were not influenced by the drug complex. The pharmacologic effect is mediated by a specific ligand-receptor interaction, since Fc receptor-positive cells are protected by an excess of unconjugated HSA and by the addition of a small amount of staphylococcal protein A, which binds to the Fc portion of IgG. These data demonstrate that Fc receptors can be exploited for cellular drug delivery using a common antigenantibody complex as a drug carrier.
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Antigen-antibody complexes can bind to mammalian cells through interaction of the constant Fc region of immunoglobulin with Fc receptors (Fc-R) on the cell surface. Although the Fc-R is found mostly in cells of the immune system (1), it is also present in certain tumor tissues and cultured tumor cells (2) . Thus the development of an Fc-R-mediated drug delivery system is relevant to both immunology and cancer chemotherapy. Recent studies have shown that Fc-R can be used to target antibody-opsonized, drug-containing erythrocytes (3) The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. lets were dissolved in 1 ml of Triton X-100 (0.1% in water). Half of each cell extract (0.5 ml) was assayed for radioactivity in a liquid scintillation counter, and the remaining 0.5 ml was used to determine protein concentration in each sample. Cell These measurements were carried out on trypsin-treated cells, and it is likely, therefore, that cell-associated radioactivity represents mostly cellular uptake, rather than surface binding. Others have noted, however, that antibody-opsonized erythrocytes will bind to the surface Fc-R of nonphagocytic cells (3) , and that Fc-R for immune complexes are trypsin resistant (1). It was important, therefore, to obtain independent evidence for a Fc-R-mediated cellular uptake of the soluble antigen-antibody drug carrier. For that purpose, we compared the effect of the MTX-HSA-anti-HSA complex on the growth of the four tested cell lines. As shown in Fig. 1 , MTX-HSA alone has no effect on the growth of either cell line, because the cellular uptake of the drug conjugate is very low (Table 1 ). This lack of inhibitory effect is consistent with the report that, in cultured L1210 cells, a MTX-bovine serum albumin conjugate was found to inhibit growth only at MTX concentrations higher than 1 AM (8) . Free MTX can inhibit the growth of all but M5076 cells (Fig. 1) . The resistance of M5076 cells to free MTX is due to a defect in membrane MTX transport in this spontaneously resistant tumor line (9) . However, when MTX-HSA is given in the presence of anti-HSA antiserum, the growth of both WEHI-3 and M5076 cells is markedly inhibited. The growth of L929 and CHO cells is not affected (Fig. 1) . That the growth inhibition of Fc-R-positive cells is due to MTX and not to an effect of the immune complex is demonstrated by the fact that the drug-free complex has no effect at all on any of the four tested cell lines. The inhibitory effect of the MTX-HSA-anti-HSA complex on the growth of M5076 cells indicates that the immune complex is taken up by the cell and is intracellularly degraded to release active drugs, as in the case of MTX-polylysine conjugates (10, 11) . Extracellular degradation of the immune complex releasing active drug would not inhibit the growth of this cell line since it is defective in MTX transport. Thus, the inhibitory effects of the MTX-HSA-anti-HSA complex shown in Fig. 1 must be due to the cellular uptake of soluble immune complex. Fig. 1 also shows that this endocytotic transport is equally effective in phagocytotic and nonphagocytotic Fc-R-bearing cells. Table 2 shows that the addition of protein A, a ligand known to bind to the Fc portion of IgG (12) , can abolish the growth-inhibitory effect of the MTX-HSA-anti-HSA complex on WEHI-3 cells. This protection offers further evidence that endocytosis of the MTX-containing immune complex is mediated by surface Fc-R. The fact that only a small amount of protein A (i.e., 2 ug/ml) is required to achieve complete protection, even when cells are tested in a medium containing 10% fetal calf serum and hence a high level of calf IgG, is possibly due to the high affinity of protein A for the free or complexed rabbit IgG (12) . This view is supported by Competition between drug-free and drug-containing HSA for the immune complex formation is also shown in Table 2 . When WEHI-3 cells are exposed to constant amounts of MTX-HSA and antiserum, and increasing concentrations of drug-free HSA, cell growth is increasingly restored ( Table  2) . This protection is due to the formation of the drug-free immune complex, competing for binding to the Fc-R. It also illustrates the fact that the drug-free immune complex is nontoxic to this cell line.
Our data demonstrate that a common soluble antigen can be an effective drug carrier when combined to a specific antiserum, and that the resulting immune complex can be selectively toxic to Fc-R-bearing tumor cells, even when such cells are nonphagocytotic. This finding should offer a tool to immunologists who wish to kill Fc-R-positive cells and to select Fc-R-negative mutants in cultured macrophage cell lines (3, 13) . The effective killing of an otherwise drugresistant cell line confirms that a macromolecular drug carrier can be superior to free drug when its endocytosis circumvents a defective drug transport system (10, 11) . Last, our data reinforce the notion that receptor-mediated endocytosis can be exploited for the development of drug-targeting systems in cancer chemotherapy.
